| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -514,770 | -509,366 |
| Depreciation and amortization | 113,402 | 74,880 |
| Non-cash impairment charges | 511,365 | 511,365 |
| Deferred income tax benefit | -55,316 | -46,663 |
| Share-based compensation | 12,745 | 7,165 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 4,590 | 3,275 |
| Non-cash lease expense | -906 | -599 |
| Loss on disposal of property and equipment | -490 | -494 |
| Change in fair value of contingent consideration and others | -14,644 | -203 |
| Accounts receivable | -15,967 | 6,540 |
| Inventories | 43,419 | 20,074 |
| Prepaid expenses and other current assets | 4,994 | 21,216 |
| Other non-current assets | -3,335 | -2,334 |
| Accounts payable, accrued expenses and other current liabilities | 3,704 | -2,078 |
| Contract liabilities | 2,715 | 2,344 |
| Other non-current liabilities | 4,304 | 2,544 |
| Net cash provided by operating activities | 38,568 | -2,338 |
| Purchases of property and equipment | 64,222 | 49,066 |
| Cash paid for business acquisitions, net of cash acquired | 0 | 0 |
| Purchases of short-term investments | 8,502 | 8,502 |
| Proceeds from maturities of short-term investments | 0 | - |
| Net payments from swaps designated as net investment hedges | 432 | - |
| Net cash used in investing activities | -73,156 | -57,568 |
| Proceeds from borrowings of long-term indebtedness | 671,000 | 67,300 |
| Payments on debt | 69,819 | 31,131 |
| Repayments of convertible debt | 574,983 | - |
| Payment of debt issuance costs | 3,930 | 3,855 |
| Purchases of treasury stock | 221 | 221 |
| Payments for contingent considerations | 16,451 | 16,451 |
| Proceeds from exercised stock options | 957 | 957 |
| Cash taxes paid in net equity settlement | 2,560 | 2,361 |
| Net cash provided by financing activities | 3,993 | 14,238 |
| Effect of exchange rate changes on cash and cash equivalents | 16,406 | 17,207 |
| Net decrease in cash and cash equivalents | -14,189 | -28,461 |
| Cash and cash equivalents at beginning of period | 246,375 | - |
| Cash and cash equivalents at end of period | 232,186 | - |
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)